Home โ€บ Mental Health โ€บ Clinical Trial
Clinical Trial ยท PHASE3 ยท Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

08 September 2026 NCT07220083 ClinicalTrials.gov โ†—
✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
12 Years+

About This Trial

PODOMOUNT-pFSGS

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.

Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.

Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.

Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Who Can Join?

Inclusion criteria: 1. Male or female participants โ‰ฅ12 years old on the day of signing informed consent/assent (Visit 1) 2. Weight of โ‰ฅ40 kg at the screening visit (Visit 1) 3. Body mass index (BMI) of โ‰ค40 kg/mยฒ at the screening visit (Visit 1) 4. Participants with a diagnosis prior to the screening visit (Visit 1) of either: * Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR * Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test) 5. Urine protein-creatinine ratio (UPCR) โ‰ฅ1500 mg/g based on the mean of the spot urine sample and first morning void (FMV) urine sample (both assessed by central laboratory) at the screening visit (Visit 1) 6. Estimated glomerular filtration rate (eGFR) * For adult participants (โ‰ฅ18 years): โ‰ฅ25 mL/min/1.73 mยฒ (chronic kidney disease…

⚠ Always speak to your doctor before applying to any clinical trial.

Clinical trials can speed up access to new treatments

Joining a trial may give you access to cutting-edge therapies before they're widely available on the NHS — while helping advance medical research.

More Mental Health Trials

Free health updates

Stay one step ahead
of your condition.

New trial alerts, treatment news, and plain-English updates โ€” matched to your condition. Free forever.

No spam. Unsubscribe anytime. Your data is private.